...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Health Services Research >A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
【24h】

A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

机译：德国医院管理视角下CDI复发性高风险患者Bezlotoxumab与护理抗生素标准的预算影响分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1?A guideline recommendation for prevention of CDI, after randomized clinical trials demonstrated its superior efficacy vs. placebo. The budget impact analysis at hand is focused on patients at high risk of CDI recurrence. Treatment with standard of care (SoC)? ?bezlotoxumab was compared with current SoC alone in the 10 most associated Diagnosis Related Groups to identify, analyze, and evaluate potential cost savings per case from the German hospital management perspective. Based on variation in days to rehospitalization, three different case consolidation scenarios were assessed: no case consolidation, case consolidation for the SoC? ?bezlotoxumab treatment arm only, and case consolidation for both treatment arms. On average, the budget impact amounted to € 508.56 [range: € 424.85 - € 642.19] for no case consolidation, € 470.50 [range: € 378.75 - € 601.77] for case consolidation in the SoC? ?bezlotoxumab treatment arm, and € 618.00 [range: € 557.40 - € 758.41] for case consolidation in both treatment arms. The study demonstrated administration of SoC? ?bezlotoxumab in patients at high risk of CDI recurrence is cost-saving from a hospital management perspective. Reduced length of stay in bezlotoxumab treated patients creates free spatial and personnel capacities for the treating hospital. Yet, a requirement for hospitals to administer bezlotoxumab is the previously made request for additional fees and a successful price negotiation.
机译：梭菌缺乏酸纤维纤维素感染（CDI）是主要的医院感染之一，导致医院的住宿时间增加和额外的治疗成本。 Bezlotoxumab是一种针对CDI的第一单克隆抗体，有一个1？在随机临床试验后，预防CDI的指导建议证明了其优越的疗效与安慰剂。手中的预算影响分析专注于CDI复发性高风险的患者。护理标准（SOC）治疗？ ？Bezlotoxumab与当前的SoC单独在10个最相关的诊断相关组中进行比较，以识别，分析和评估每个案例的潜在成本节约，从德国医院管理的角度来看。基于对Rehospization的日子的变化，评估了三种不同的案件整合情景：无案例合并，SOC的案例合并？ ？Bezlotoxumab处理臂，以及两种治疗臂的壳体固结。平均而言，预算影响达508.56欧元[范围：€424.85 - €642.19]对于无案例合并，€470.50 [范围：€378.75 - €601.77]在SOC中综合综合综合？ ？Bezlotoxumab治疗臂，618.00欧元[范围：€557.40 - €758.41]，以便在两种治疗臂中合并。这项研究表明了SoC的管理？ ？在CDI复发风险高风险的患者中Bezlotoxumab是从医院管理的角度节省成本节约。减少贝茨毒素治疗患者的逗留时间为治疗医院创造免费的空间和人员能力。然而，医院需要管理Bezlotoxumab的要求是先前提出的额外费用和成功的价格谈判。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号